###### Strengths and limitations of this study

-   This study provides a timely update to the cost of smoking in Singapore as the last publication was dated 2002.

-   The study also attempts to provide a more accurate reflection of the societal cost by including the cost of presenteeism and healthcare costs incurred in subsidised hospital wards.

-   However, the cost data reflected remain as an underestimate of the true cost due to a lack of data.

Introduction {#s1}
============

There is robust evidence on the negative impact of tobacco smoking on individuals\' health. Studies have shown that smoking directly causes or increases the risks of cardiovascular and respiratory diseases,[@R1] [@R2] various types of cancers[@R3] and diabetes.[@R6] Non-smokers are also subjected to heightened risks of these diseases due to secondhand smoke.[@R7] [@R8] From a global perspective, ∼6 million people die each year from smoking and another 600 000 deaths occurred due to the effects of secondhand smoke, higher than the death tolls from tuberculosis, HIV/AIDS and malaria combined.[@R9]

Singapore has often been lauded for taking a tough stance on tobacco. Smoking prevalence is currently relatively low---14.3% in 2010 (24.7% for men, 4.2% for women),[@R10] which may be attributed to its strong ongoing commitment to the WHO Framework Convention on Tobacco Control (FCTC), under which the government introduced a series of policies including underage smoking restrictions, warning labels, restricted advertising and high taxation. More recently, developments include a 10% hike in tobacco excise tax in 2014,[@R11] the Health Promotion Board\'s 'I Quit' campaign,[@R12] the banning of shisha in 2014[@R13] and the ban on electronic cigarettes and other emerging tobacco products in 2015.[@R14]

In 1997, prior to many of these concerted actions, Quah *et al*[@R15] estimated that the social cost of smoking in Singapore ranged from US\$530.4 million (SGD673.6 million) to US\$660.6 million (SGD839.2 million). The objective of this paper is therefore to revisit the social cost of smoking after almost two decades of anti-tobacco policies in Singapore and to assess the implications of a recent resurgence in smoking prevalence in the light of this re-examination.

Methods {#s2}
=======

The impact of smoking on society is not just the medical cost. It also includes an indirect cost such as the loss of productivity from smoking-related diseases ([figure 1](#BMJOPEN2016014377F1){ref-type="fig"}). In this paper, we used a prevalence-based approach to measure the cost of smoking in a specific time period.[@R16] The smoking attributable expenditure (SAE) estimated from the society\'s perspective consisted of direct inpatient medical costs and indirect costs due to loss of productivity from illness (absenteeism), smoking breaks (presenteeism) and the cost of premature mortality. The cost of premature mortality refers to the economic losses incurred by society when a person dies at a younger age than expected age due to smoking. Meanwhile, the loss of productivity was estimated by absenteeism---that is, when the person is not at work due to illnesses related to smoking or present at work (presenteeism) but has lower productivity.

![Cost conceptual framework.](bmjopen-2016-014377f01){#BMJOPEN2016014377F1}

Data sources {#s2a}
------------

To evaluate the cost of smoking in Singapore, population smoking-attributable fractions (SAF) of various diseases were estimated based on a 2010 (unpublished) Singapore Comparative Risk Assessment Study conducted by the Singapore Ministry of Health (MOH). Gender-specific and age group-specific (5-year interval) estimated SAFs of mortality for 19 diseases in 2010 between ages 0 and 85 years and over were calculated. As in other regional studies with limited data (see, for instance, Taiwan[@R19] and Vietnam[@R20]), these SAFs of mortality were used as best available proxies for SAF of overall disease burden. The overall SAF figures for each disease are listed in [table 1](#BMJOPEN2016014377TB1){ref-type="table"}. Disease-specific hospital bill size data were retrieved from the MOH website.[@R21] Gender-specific and age group-specific (10-year interval) smoking prevalence was reported in the 2010 National Health Survey.[@R10] Finally, data on 2014 gender-specific and age group-specific median incomes, labour participation rates and population figures were derived from the Ministry of Manpower (MOM)[@R22] and the Department of Statistics Singapore. Given the nature of the data sources, this study was exempted from ethics review. The social cost of smoking was estimated for Singaporeans and permanent residents aged 20 years and above. All reported costs are in US dollars (where US\$1=SG\$1.27) for the year 2014.

###### 

Overall SAF by gender in 2010

                                      SAF (%)\*†   
  ----------------------------------- ------------ -------
  Mouth cancer                        0.47         0.34
  Oesophagus cancer                   0.47         0.48
  Lung cancer                         0.87         0.71
  Larynx cancer                       0.69         0.66
  Pancreas cancer                     0.20         0.21
  Bladder cancer                      0.36         0.41
  Kidney cancer                       0.45         0.41
  Stomach cancer                      0.19         0.12
  Uterus cancer                       N.A.         −0.24
  Ischaemic heart disease             0.16         0.02
  Stroke                              0.13         0.01
  COPD                                0.53         0.67
  Parkinson's disease                 −0.13        −0.01
  Lower respiratory tract infection   0.05         0.01
  Low birth weight                    0.03         0.05
  Fire injuries                       0.23         0

\*The SAF figure takes into account passive smoking.

†SAF figures for three other diseases---otitis media, asthma and age-related macular degeneration---were provided. SAF for otitis media and asthma was 0 across all age groups in Singapore\'s context and there were no deaths due to age-related macular degeneration in Singapore, so the SAF for these two diseases were not included in the table.

COPD, chronic obstructive pulmonary diseases; SAF, smoking-attributable fraction.

Estimation of SAF {#s2b}
-----------------

The calculation of the SAF followed the methodology of the Australian Burden of Disease Report 2003.[@R23] Using this methodology, the SAF for mortality may not be directly estimated from current smoking prevalence due to the long lag time between smoking exposure and certain diseases, particularly cancers. For such diseases, 'smoking impact ratio (SIR)' was calculated. The age group-specific and gender-specific SIR was expressed as a comparison of the excess mortality due to lung cancer in Singapore, and the excess mortality due to lung cancer in a well-studied reference population, the American Cancer Society\'s Cancer Prevention Study II.

where C~LC~ denotes the number of lung cancer deaths in current smokers in Singapore, N~LC~ is the number of lung cancer deaths in non-smokers in Singapore, is the number of lung cancer deaths in smokers in the reference population and denotes the number of lung cancer deaths in non-smokers in the reference population.

The SIR figure was subsequently used to replace smoking prevalence in the calculation of the SAF of mortality for chronic obstructive pulmonary diseases (COPD) and other types of cancers. For non-cancers, SAF for mortality was calculated using smoking prevalence rates.

where RR~i~ denotes the disease-specific mortality risk ratio.

Medical cost {#s2c}
------------

Direct medical cost was calculated based on four major diseases associated with smoking (lung cancer, ischaemic heart disease, stroke and COPD), for which data on hospital inpatient bill size for a sample of public and private hospitals were made publicly available by MOH. Data on outpatient bills and out-of-pocket expenditures were unfortunately not available.

In Singapore, ward class determines the total cost of care and the amount of subsidy patients get, from 0% in class A wards (with full amenities such as private rooms and air-conditioning) to almost 80% subsidy in class C wards (with more limited amenities and means-tested access).[@R24] The publicly available data provide inpatient volume as well as the 50th and 90th centile cost for each disease by hospital and ward class.

Average hospital bill sizes between 1 Feb 2014 and 31 January 2015 were estimated by assuming that bill sizes followed a hospital and ward-class-specific lognormal distribution and solving for the mean disease-specific hospital bill size for each ward class in the respective hospitals given the reported percentile values. Given the societal perspective of the analysis, subsidies provided for lower class wards were then factored back into the calculation to recover estimated total actual healthcare costs.

In the absence of more specific demographic breakdowns, we also assumed the age-specific, gender-specific and disease-specific proportions of inpatient volume to be the same as the observed age-specific, gender-specific and disease-specific proportions of mortality. For example, in the case of lung cancer, ∼7.3% of the deaths were of men aged 60--64 years, and we therefore attributed 7.3% of the total inpatient volume to men aged 60--64 years.

The direct medical cost of smoking was then estimated based on the disease-specific average estimated cost (in each hospital and ward class) multiplied by patient volume, taking into account the SAF. Owing to a lack of data, healthcare costs from the primary health sector (ie, private general practitioners\' clinics and polyclinics), the intermediate and long-term care sector (including nursing home and community hospitals), as well as the cost of other smoking-related diseases such as stomach and kidney neoplasms, were not included.

Indirect cost {#s2d}
-------------

On the basis of the human capital approach,[@R25] the monetary value of lost productivity was assumed to be equal to the wage rate. The economic impact of absenteeism from work was calculated by multiplying the average age-specific and gender-specific daily wages by the average length of stay (LOS) for the four diseases stated above, accounting for SAF, age-specific and gender-specific inpatient volume proportions and labour participation rate.

Approximately 25% of the population aged 70--75 years and 10% of the population aged 75 and over reported working in 2015. However, the MOM reports age-specific salary rates only up to the category '60 and over'. Salary estimates for individuals above 70 are likely to be significantly lower or may need to account for part-time work, but cannot be reliably estimated from the existing data. As a result, to be conservative, unlike the calculation for direct healthcare cost, we include productivity costs only for individuals aged 69 and below. Total LOS was determined by multiplying the disease-specific inpatient volume for each hospital ward class with their respective average LOS. Overall average LOS for each disease was then determined by dividing the total LOS by the total volume.

To estimate the economic impact of premature deaths, in addition to a smoker\'s current salary, the value of his/her lost future productivity (proxied for by future salary up to age 69 years) was taken into account and discounted to derive the present value as of 2014. The present cost of forgone lifetime earnings (PVLE) was thus calculated as total smoking attributable deaths across the 19 diseases, multiplied by the labour participation rate and expected future earnings at a discount rate of 3%. The income growth rate was arbitrarily set at 2%, as the annualised change in real wages between 2009 and 2014 was 2%.[@R26]

Finally, the cost of smoking breaks was estimated based on the assumption that smokers only take one 10-min smoking break daily. We used this as the baseline scenario on the basis that this most likely represents a reasonable lower-bound estimate. Given that smoking breaks require long trips outside due to smoking area restrictions, this assumption is likely to be conservative. While there are no local published studies that formally substantiate this assumption, this was consistent with unpublished observational data gathered in other studies conducted by local principal investigators and also reflected the principle of conservatism. We then estimated productivity losses taking into consideration the size of the workforce, gender-specific and age group-specific smoking prevalence and wages. [Table 2](#BMJOPEN2016014377TB2){ref-type="table"} describes the cost estimation formulas.

###### 

Cost estimation calculations

  Types of cost                       Cost estimation
  ----------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Direct cost                         
   Medical cost of hospitalisations   Death proportion~iga~ \* inpatient volume~iga ~\* average healthcare cost~ig ~\* SAF~iga~
  Indirect cost                       
   Loss of productivity               Death proportion~iga ~\* inpatient volume~iga ~\* average LOS~ig ~\* Labour participation rate~ga ~\* daily wage~ga ~\* SAF~iga~
   Premature deaths cost              Number of deaths~ga ~\* labour participation rate~ga ~\* total expected future earnings \* SAF~ga~
   Smoking breaks                     Total population~ga~ \* labour participation rate~ga ~\* smoking prevalence~ga ~\* wages by minutes~ga ~\* number of smoking break \* length of smoking break (min)

Here i=1,...,nth disease; j=gender; a=age group (5-year interval).

LOS, length of stay; SAF, smoking-attributable fraction.

Results {#s3}
=======

Baseline results---a conservative scenario {#s3a}
------------------------------------------

A conservative estimate of the social cost of smoking in Singapore in 2014 was at a minimum of US\$479.8 million as shown in the baseline scenario in [table 3](#BMJOPEN2016014377TB3){ref-type="table"}. For all cost components, the cost of smoking was higher in men due to a higher smoking prevalence. Direct healthcare costs were relatively low, US\$12.5 million for men and US\$2.4 million for women. Absenteeism costs amounted to US\$943 232 for men and US\$52 601 for women. Presenteeism (smoking breaks) accounted for 56% of the total cost incurred, with US\$239.2 million and US\$29.8 million, respectively, for men and women. Finally, premature mortality cost society an additional US\$195 million, taking up 40.6% of the total cost.

###### 

Overall cost of smoking

  Estimates                Baseline Estimates (US\$)   
  ------------------------ --------------------------- ------------
  Direct healthcare cost   12 513 611                  2 398 949
  Absenteeism              943 232                     52 601
  Presenteeism             239 214 947                 29 750 790
  Premature mortality      182 237 404                 12 710 266
  Subtotal                 434 909 194                 44 912 606
  Total                    479 821 799                 

For direct healthcare cost, approximately half (50.4%) of the cost incurred by men was due to ischaemic heart disease (US\$6.3 million), followed by lung cancer (US\$2.8 million), COPD (US\$1.7 million) and stroke (US\$1.6 million). In women, it was lung cancer (US\$1.1 million), followed by ischaemic heart disease (US\$596 084), COPD (US\$523 226) and stroke (US\$193 954).

Loss of productivity due to diseases amounted to US\$995 883. Out of the four diseases, the majority (50.4%) of the absenteeism cost for men was attributed to ischaemic heart diseases (US\$420 178) followed by stroke, lung cancer and COPD, while for women it was lung cancer (US\$28 331), followed by stroke, ischaemic heart disease and COPD ([table 4](#BMJOPEN2016014377TB4){ref-type="table"}).

###### 

Cost of smoking by disease

  Disease                   Direct healthcare cost (US\$)   Absenteeism (US\$)             
  ------------------------- ------------------------------- -------------------- --------- --------
  Lung cancer               2 828 307                       1 085 685            194 457   28 331
  Ischaemic heart disease   6 302 899                       596 084              420 178   10 141
  Stroke                    1 634 615                       193 954              260 163   11 742
  COPD                      1 747 789                       523 226              68 434    2387
  Subtotal                  12 513 611                      2 398 949            943 232   52 601
  Total                     14 912 560                      995 833                        

COPD, chronic obstructive pulmonary disease.

Scenario analysis {#s3b}
-----------------

We further explored four different scenarios that capture the uncertainty in our baseline assumptions as well as future developments: (1) increases in number of smoking breaks taken; (2) increases in smoking prevalence; (3) income growth; and (4) increased scope for presenteeism ([table 5](#BMJOPEN2016014377TB5){ref-type="table"}).

###### 

Scenarios affecting overall cost of smoking

  Estimates                Baseline      Baseline+three smoking breaks   Increase smoking prevalence   Increase income growth   Partial disability cost                                                         
  ------------------------ ------------- ------------------------------- ----------------------------- ------------------------ ------------------------- ------------ ------------- ------------ ------------- ------------
  Direct healthcare cost   12 513 611    2398 949                        12 513 611                    2 398 949                19 496 769                14 536 507   12 513 611    2 398 949    12 513 611    2 398 949
  Absenteeism              943 232       52 601                          943 232                       52 601                   878 172                   153 125      943 232       52 601       943 232       52 601
  Presenteeism             239 214 947   29 750 790                      717 644 842                   89 252 370               577 494 800               30 083 884   239 214 947   29 750 790   242 973 820   29 936 918
  Premature mortality      182 237 404   12 710 266                      182 237 404                   12 710 266               156 339 540               31 655 398   229 369 294   15 779 891   182 237 404   12 710 266
  Subtotal                 434 909 194   44 912 606                      913 339 088                   104 414 185              754 209 281               76 428 914   482 041 084   47 982 231   438 668 066   45 098 734
  Total                    479 821 799   1 017 753 274                   830 638 195                   530 023 315              483 766 800                                                                     

Increasing the assumed frequency of smoking breaks has the highest impact on the overall cost of smoking. On the basis of a previous review of the literature in the USA and Canada, a reasonable upper-bound estimate of time loss would be 30 min a day of unsanctioned smoking.[@R27] Applying this to our calculations would proportionally triple lost societal value, from US\$270.0 million to US\$807.9 million, and results in an overall SAE of about US\$1.0 billion.

In our second scenario, we modelled a potential increase in smoking prevalence in a comparable population by using historical SAF and prevalence figures for South Korea as reported by Kang *et al*,[@R28] extrapolating their SAF figures beyond age 64 years to correspond to our analysis. In 1992, prevalence of smoking was ∼66% for men and 7% for women in South Korea for people aged 30 years and over.[@R29] Cost increases under this scenario mainly occurred under the presenteeism category, reaching US\$607.6 million in total while overall SAE reached US\$830.6 million, a 73.1% increase from our baseline scenario.

In the third scenario, projecting a 5% income growth (with a 3% inflation rate) increased the present-valued cost of premature deaths. For men, the figure increased from US\$182.2 million to US\$229.4 million and for women, it increased from US\$12.7 million to US\$15.8 million. Overall, SAE increased by 10.5% to US\$530.0 million due to the increased mortality cost.

Finally, we included a fourth scenario to address the fact that beyond smoking breaks, presenteeism can also be caused by lower productivity while actively working (ie, partial disability). In the absence of such data for Singapore, we used the average count of partial disability work days from a sample of high-income countries in three categories (cardiovascular, respiratory and cancer) to proxy for this aspect of presenteeism cost.[@R30] Further, including the value of partial disability days (at average wages) into our estimates of total productivity loss had a minimal impact. It increased the overall presenteeism cost from USD269.0 million to USD272.9 million, resulting in a 0.82% increase in overall cost of smoking to USD483.8 million. Since the impact is minimal and the estimates indirect, we excluded this from our baseline scenario, but presented the results here for completeness.

Discussion {#s4}
==========

This study estimated that cigarette smoking cost Singapore at least US\$479.8 million in 2014. A majority of the cost is likely to come from presenteeism (US\$269.0 million) and to be concentrated among males (US\$435.0 million). In terms of diseases, ischaemic heart disease (US\$7.3 million) and lung cancer (U\$4.1 million) cost the most out of the four diseases, due to higher SAF figures and more costly treatments.

In 2014, Singapore generated US\$908.5 million in tobacco excise tax revenues,[@R31] a 'benefit' that surpassed this estimated societal cost. Our conservative baseline estimate of societal cost in 2014 is ∼10% lower than the range of US\$530.4 million---US\$660.8 million estimated for 1997.[@R15] At 0.2% of the national GDP, this estimate is also comparatively low relative to published figures for Asian peers such as South Korea (0.6--1.2%),[@R28] China (0.7%),[@R32] Taiwan (0.4%)[@R19] and Vietnam (1.0%).[@R20]

However, these findings by no means imply that the time for stringent tobacco control policy is over. We emphasise that the cost estimate should be interpreted as a minimum figure, underestimating the true societal cost. First, our methodology is limited by the constraints of data availability and most likely significantly understates the true costs. As noted, we are able to include only four smoking-related diseases for direct healthcare cost calculation. SAFs for mortality were used to calculate morbidity cost, although the disease-specific relative risks of the latter may be higher, leading to unattributed costs of healthcare and indirect morbidity. Smoking-related costs incurred by smokers, passive smokers and ex-smokers in the primary healthcare sector, rehabilitation care and nursing homes, or due to self-medication, were also excluded due to a lack of reported data. While this study has attempted to capture the cost of presenteeism, we could not include other indirect costs such as the cost of implementing tobacco control programmes, cost of cigarette purchases and the potentially large externality costs of secondhand smoke. Finally, we did not account for the rising use of a variety of alternative tobacco products for which data are not readily available and will not be for some time.

Comparisons across time and peer groups are further complicated by methodological differences and may be misleadingly optimistic if taken purely at face value. The difference between our estimates for 2014 and the estimates for 1997 suggests a fall in total societal costs, consistent with survey data showing a fall in smoking prevalence from 15.1% in 1998 to 14.3% in 2010. Shorter hospital stays in the present day, updated treatment procedures, fewer smoking-related deaths and deaths at an older age could also potentially play a role. However, the study was not designed to test these hypotheses formally due to fundamental differences in data sources and the resulting calculations. Using restricted MOH data, Quah *et al* accounted for the direct healthcare cost of five conditions (oesophageal cancer, larynx neoplasm, trachea, bronchus and lung cancer, ischaemic heart and cerebrovascular heart diseases). In contrast, this study relied on publicly available statistics on hospital bills for only four conditions (lung cancer, COPD, ischaemic heart diseases and stroke). Second, Quah *et al*[@R15] assumed that unit costs are uniformly based on the charges of Class A wards (the highest class of service in public hospitals, equivalent to private wards), which overestimates total population costs. Smoking prevalence tends to be higher among lower-income households, leading to a large fraction of patients who use lower-class wards with more limited amenities, in which unit costs are significantly lower (even after accounting for government subsidies). Our estimates included data from all ward classes in the public hospitals as well as data from private hospitals. In this respect, the cost estimated in this study is a more accurate reflection of inpatient medical costs at the population level. We also noted that our study methodology was not always more conservative than Quah *et al*,[@R15] as a broader consideration of lost productivity was included.

The cross-country comparisons are subjected to similar methodological caveats. For example, Kang *et al*[@R28] estimated the cost of 22 smoking-related diseases in South Korea while Yang *et al*[@R32] also included caregivers\' cost in the calculation of the monetary value of indirect morbidity in China.

Looking to the future, in spite of stringent controls and health promotion programmes, declines in smoking prevalence have reversed in certain groups. Smoking prevalence has increased among adolescent men from 7.7% in 2009 to 8.8% in 2012. In addition, overall female smoking prevalence has also risen from 3.3% in 2004 to 4.2% in 2010. If these trends persist, the future social cost of smoking will correspondingly rise. As Singapore ages, rising healthcare costs are likely to further compound this increase. Finally, with new policy efforts to increase overall productivity growth and employment in old age, indirect losses from morbidity and premature mortality will also become more significant.

To address the limitations of our study and smoking research in Singapore more generally, further studies will be needed including better research on the SAF of morbidity, estimates of patient volumes and costs in the primary care sector and studies of cost incurred by caregivers. Over the longer term, ongoing efforts to develop integrated national electronic health records will also help to enable systematic collection of data on other risk factors and diseases as part of a more robust platform for measuring the socioeconomic burden of diseases over time.

At the same time, various stakeholders can already benefit from the insights of this work. Taken together, our findings suggest that for Singapore, implementing new and more effective efforts to prevent uptake of smoking among the young is an urgent need, while encouraging quitting among current smokers at every age still remains a priority. The MOH and MOM need to work together with employers to reduce the cost of lost productivity in workplaces, and other entities outside the health system such as the Ministry of Education to address smoking at younger ages. The case of Singapore demonstrates that effective long-term tobacco control must be firm and sustained and requires adaptation and multisector collaborations in the face of new and emerging trends in tobacco use.
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